Institute of Pathology, Hubertus-Wald-Cancer-Center, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
Institute of Pathology, Hubertus-Wald-Cancer-Center, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
Oral Oncol. 2012 Oct;48(10):991-996. doi: 10.1016/j.oraloncology.2012.05.005. Epub 2012 Jun 12.
Epidermal growth factor (EGFR) is involved in angiogenesis, cell differentiation, proliferation and progression of many cancers and is an important therapy target in lung and colorectal cancer. To determine the potential applicability of EGFR targeted therapies, EGFR status of over 800 salivary gland tumors of different entities were analyzed on DNA and protein level by FISH and IHC.
A tissue microarray was constructed from 721 carcinomas and 205 adenomas of the salivary gland. EGFR expression and EGFR gene copy number was assessed by means of immunohistochemistry and fluorescence in situ hybridization (FISH). EGFR mutation analysis of exon 19 and 21 was performed in a subset of 107 carcinomas.
Positive immunohistochemical staining (definition?) for EGFR was shown in 324 of 663 (48.9%) salivary gland carcinomas. The frequency was dependent on the tumor entity and ranged from 17.9% (30 of 168 cases) positive immunostaining in acinic cell adenocarcinomas to 85.7% (42 of 49 cases) in Warthin tumors. No EGFR amplification was found by FISH. EGFR mutation analysis of Exon 19 and 21 in 107 salivary gland carcinomas revealed mutations in two acinic cell adenocarcinomas.
EGFR protein expression is common in salivary gland tumors but is not associated with gene amplification. Activating mutations of EGFR are rare. Nonetheless, selected cases of patients with salivary gland carcinomas might potentially benefit of anti-EGFR therapy.
表皮生长因子（EGFR）参与许多癌症的血管生成、细胞分化、增殖和进展，是肺癌和结直肠癌的重要治疗靶点。为了确定 EGFR 靶向治疗的潜在适用性，通过荧光原位杂交（FISH）和免疫组织化学（IHC）在 DNA 和蛋白质水平上分析了 800 多种不同实体的唾液腺肿瘤的 EGFR 状态。
从 721 例唾液腺癌和 205 例腺瘤中构建了组织微阵列。通过免疫组织化学和荧光原位杂交（FISH）评估 EGFR 表达和 EGFR 基因拷贝数。对 107 例癌中的亚组进行了外显子 19 和 21 的 EGFR 突变分析。
663 例唾液腺癌中有 324 例（48.9%）显示 EGFR 免疫组织化学染色阳性（定义？）。阳性率取决于肿瘤实体，范围从 17.9%（30/168 例）在腺泡细胞腺癌中到 85.7%（42/49 例）在沃辛瘤中。未通过 FISH 发现 EGFR 扩增。对 107 例唾液腺癌的外显子 19 和 21 的 EGFR 突变分析显示，在 2 例腺泡细胞腺癌中存在突变。
EGFR 蛋白表达在唾液腺肿瘤中很常见，但与基因扩增无关。EGFR 的激活突变很少见。尽管如此，一些唾液腺癌患者可能会受益于抗 EGFR 治疗。
